Nasopharyngeal Carcinoma
Conditions
Keywords
nasopharyngeal carcinoma, programmed death-ligand 1, prognosis
Brief summary
The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.
Detailed description
NPC is a common type cancer in Macau and Southern China. The role of PD-L1 in NPC remains controversial. There many reasons behind these inconsistent findings. We used the SP263 antibody with the standard cut off value of 1% and 5%, which is frequently used for lung cancer and other cancer types. We also plan to include over 150 patients, which will be the largest study in NPC. This will help us to gain insights in NPC.
Interventions
RADIATIONRadiation
Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
Sponsors
Kiang Wu Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Above 18 years of age * Locally advanced (stage IIIB) or metastatic (stage IV) NPC * Fresh-frozen tissue samples were available were included * After treatment with curative surgery or radiotherapy in Macau * With follow up data were available
Exclusion criteria
• Enrolment in studies that prohibit any participation in this observational study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | Followed up with 12 months after last patient in | Efficacy after radiation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival rate | Followed up with 12 months after last patient in | Survival in PD-L1 positive and negative group |
Countries
China
Outcome results
None listed